How to dose GHK-Cu

GHK-Cu dosing: the essentials

• The standard dosing for subcutaneous GHK-Cu in research is 1–2 mg a day in cycles of 4–8 weeks, within a practice range of 0.5–2 mg a day, with the dose tiered according to the research goal in question (skin, wound healing, anti-inflammatory action, hair).
• The pen comes pre-filled with 50 mg and the dose dial marks the dose directly in milligrams: there is nothing to prepare and there are no volumes to calculate.
• Cycles of 4–8 weeks followed by a washout of 2–4 weeks, in order to keep copper homeostasis under control and to prevent the receptors from becoming desensitised.
• As of 2026 there is no published subcutaneous randomised controlled trial in humans; all of the dosing comes from animal models, from cell cultures and from practice protocols.
• Change the injection site every day, rotating between the abdomen, the thigh and the flank, in order to avoid lipodystrophy and to keep absorption uniform.

In research applications, the GHK-Cu peptide is usually dosed by the subcutaneous route at a rate of 1–2 mg a day, in cycles that last 4–12 weeks, with the exact range tied to the particular research goal that is being modelled. As of 2026 there are no published subcutaneous studies in humans [2], so the table below matches the ranges that are cited in practice to specific goals (skin, wound healing, anti-inflammatory work and hair), together with cycle conventions derived from the short plasma half-life of GHK-Cu, which is around 5–30 minutes [2][5].

This guide covers the standard subcutaneous dosing range that is used for research with GHK-Cu (0.5–2 mg a day), how to handle the pen, and how to structure the active cycle and the washout phases on the basis of published practice protocols and of mechanistic reasoning.

What GHK-Cu is and why the dosing matters

GHK-Cu is glycyl-L-histidyl-L-lysine-copper(II), a naturally occurring tripeptide found in human plasma that binds copper with high affinity and modulates wound repair, the anti-inflammatory pathways and the remodelling of the extracellular matrix [2]. The molecule was first isolated from human plasma in 1973, and since then it has been characterised in models of skin regeneration, of hair follicle stimulation and of tissue repair [2][3].

The endogenous plasma concentrations of GHK fall sharply with age, and that is the mechanistic rationale on which most of the supplier literature bases the case for exogenous dosing in research [3]. Pickart and colleagues described values of around 200 ng/ml in young adults that drop below 80 ng/ml by the age of 60; this is context on the endogenous levels, not a dosing target. As of 2026, no published subcutaneous study in humans has either reproduced or pursued those plasma concentrations with injection protocols [2].

Why dose precision matters

Copper is biologically active even when it is present at low concentrations, and the GHK carrier is what makes it bioavailable to tissue [2]. Falling short on the dose risks sub-therapeutic exposure for research goals that already have short pharmacokinetic windows of their own (plasma half-life ≈5–30 minutes [2][5]). Going over it raises the theoretical concern of a cumulative load of copper, although within the SC range of 0.5–2 mg a day no GHK-Cu-specific shifts in ceruloplasmin or in serum copper have actually been measured. Some researchers are concerned that combining GHK-Cu with other repair peptides may increase the exposure to copper; consult the BPC-157 and TB-500 dosing protocol and the wider index of peptide guides and dosing protocols before settling on a regimen.

GHK-Cu is supplied exclusively as a research peptide; nothing in this guide constitutes clinical advice of any kind [6].

The GHK-Cu dosing protocol at a glance (2026)

The standard subcutaneous research dose of GHK-Cu is 1–2 mg once a day, in cycles of 4–8 weeks followed by a break of 2–4 weeks, with 0.5 mg as the exploratory anchor at the lower end of the range and 2 mg as the ceiling of the range that is cited in the current supplier protocols [1][3][5]. The table below summarises what the published practice literature says; as of 2026 there is no authorised dosing in humans of any kind [6].

2 mg a day is the ceiling of the practice range: above that figure, the literature does not describe any greater response to the compound. Anyone combining GHK-Cu with other repair compounds can consult the BPC-157 and TB-500 dosing protocol or look through the full index of peptide guides and dosing protocols for the neighbouring compounds. This table reproduces published research literature only, and it is not clinical advice.

Dose ranges by research goal

The published GHK-Cu protocols tier the dose according to the biological goal that is under study. Skin and collagen models sit at the low end (0.5–1 mg a day), wound healing and tissue repair at 1–2 mg a day, anti-inflammatory work at 1 mg a day and hair follicle stimulation at 1–2 mg a day [4][5]. Most of these figures come from data obtained in animals or in cell culture; there is no peer-reviewed subcutaneous RCT in humans that defines any of them.

Skin remodelling and collagen synthesis (0.5–1 mg a day)

The lower doses appear to be sufficient because the targets in dermal fibroblasts (procollagen 1, decorin, the modulation of MMP-2) respond in culture at picomolar or nanomolar concentrations already. In the literature, exploratory skin work is usually anchored at 0.5 mg SC once a day, and it only moves up to 1 mg if the model calls for deeper dermal involvement [4]. The cell-culture data consistently show a fibroblast response at those concentrations, so anyone wondering whether the lower doses produce measurable changes has good reason to start at that point.

Wound healing and tissue repair (1–2 mg a day)

A 2023 excision model in mice applied GHK-Cu topically at 0.5–2 mg/kg a day, with intradermal variants in a similar mg/kg range [5]. When that is carried over to the subcutaneous practice protocols, it equates to 1–2 mg a day in studies oriented towards repair, often combined with cyclical windows of 4–8 weeks [5]. Anyone combining it with other repair compounds can consult the BPC-157 and TB-500 dosing protocol for parallel cycle structures.

Anti-inflammatory and antioxidant goals (~1 mg a day)

Suppression of NF-κB and reductions in the markers of carbonyls and of peroxidation are described in vitro at GHK-Cu concentrations that are achievable, in extrapolated pharmacokinetic models, with 1 mg a day by the SC route [5]. In the practice literature, the higher doses have not shown any additional anti-inflammatory benefit over and above that [3][5].

Hair follicle stimulation (1–2 mg a day)

In the published work, hair goals are dominated by the topical and microneedling routes. The SC protocols of 1–2 mg a day are derived from those routes by practitioners, and not from any controlled study [2][4].

Why the dose ranges plateau: receptor saturation and the rationale for cycling

GHK-Cu drives tissue remodelling by activating the TGF-β and VEGF pathways [4]. The supplier literature attributes the absence of a dose-response relationship above roughly 2 mg a day to receptor saturation and down-regulation. That is the mechanistic argument in favour of cycling (4–8 weeks on, 2–4 off) rather than administering the compound continuously [5]. The full logic behind cycling is set out in the index of peptide guides and dosing protocols.

GHK-Cu cycle length: the research rationale

GHK-Cu protocols run in cycles of 4–8 weeks followed by a break of 2–4 weeks, because the published interventions rarely go beyond eight weeks and, as of 2026, there are no human safety data for continued use beyond that window [5]. The cycle structure is a cautious extrapolation from the durations of the studies and from the theory of copper metabolism; it is not a rule that has been derived from long-term controlled studies.

Copper homeostasis

A continuous exogenous supply of copper can down-regulate the expression of ceruloplasmin and of metallothionein, the two main copper-buffering proteins. Turnlund et al. (1998, American Journal of Clinical Nutrition) showed that the copper balance in humans adapts, within a matter of weeks, to sustained changes in the level of intake [7]. The supplier protocols cite this as the basis for introducing a washout phase. No study from 2023–2026 has measured ceruloplasmin or serum copper during the SC use of GHK-Cu.

Receptor desensitisation

Prolonged exposure to GHK-Cu is suspected of blunting the responsiveness to TGF-β1 in fibroblast models, which would flatten the very remodelling signal that justifies the dosing in the first place [4]. It is the same saturation logic that is put forward to explain the plateau in dose response above 2 mg a day [5].

Practical research design

Most of the published GHK-Cu interventions are topical or intradermal studies lasting 4–8 weeks; longer continuous SC protocols simply have no published precedent at all [5]. A 2-week washout phase is the minimum that is recommended in the supplier protocols [5]. Anyone structuring cycles with several peptides can consult the BPC-157 and TB-500 dosing protocol for on and off windows that are compatible with one another.

Setting the dose on the GHK-Cu pen

The GHK-Cu pen is supplied pre-filled with 50 mg, and the dose dial marks the dose directly in milligrams. There is nothing to prepare, nothing to dilute and nothing to measure: the dose called for by the protocol is read off the dial and then administered. The procedure below reflects the practice guidance that is documented in the current dosing protocols [1][5].

1. Prepare the materials. The pre-filled pen, a new pen needle and two alcohol wipes. Inspect the cartridge: the GHK-Cu solution should look very pale blue and clear. Any discolouration or any particles are grounds for discarding it.
2. Bring the pen to room temperature. Take it out of the refrigerator and let it reach room temperature before injecting.
3. Attach the needle. Clean the rubber septum with a 70% isopropyl alcohol wipe before screwing on a new needle.
4. Prime. Dial a small test dose and press until a droplet forms at the tip of the needle, in order to clear the air out of the channel.
5. Dial the dose. Turn the dose dial to the figure in milligrams that corresponds to the research goal in the tables above: 0.5 mg, 1 mg or 2 mg.
6. Record the dose and the site in the research log before returning the pen to the refrigerator.

For the handling conventions that are shared by tissue-repair peptides, see the BPC-157 and TB-500 dosing protocol, or browse the whole collection of peptide guides and dosing protocols for the neighbouring compounds.

Reported parameters for the subcutaneous administration of GHK-Cu

The published protocols describe the subcutaneous administration of GHK-Cu with a short pen needle into the fatty tissue of the abdomen, the outer thigh or the flank, changing the site every day in order to avoid local lipodystrophy. The sequence below reflects the standard subcutaneous injection technique that is documented in general terms for subcutaneous medicines, and it is reproduced here solely as a point of reference for the research context.

Reported administration sequence

1. Hand hygiene. The standard aseptic technique in the literature calls for washing the hands for 20 seconds with soap and warm water and drying them with a clean towel before touching the pen.
2. Site preparation. The protocols describe cleaning the injection site with a 70% isopropyl alcohol wipe in a single outward spiral, with around 10 seconds of air drying, since, according to reports, injecting while the alcohol is still wet stings at the moment of puncture.
3. Dial the dose. The dose is dialled in milligrams, according to the tables above.
4. Skin fold. The usual practice is to lift a fold of 2–3 cm at the chosen site between the thumb and the forefinger.
5. Needle angle. Inserting the needle at around 45° into the lifted fold is described; with short needles, a 90° puncture at a flat site (with no pinching) is described as correct.
6. Administration speed. A slow, even administration over 3–5 seconds is described, with a 5-second pause before withdrawing, in order to limit backflow.
7. Withdrawal. The protocols describe withdrawing the needle at the same angle, releasing the fold and pressing gently with dry gauze; rubbing is associated with accelerated dispersion and with bruising.
8. Needle disposal. The needle is discarded immediately into a puncture-resistant sharps container.

Injection site rotation plan

The daily change avoids repeated trauma to a single depot, something which, over weeks of daily injection, leads to lipodystrophy, to fibrotic nodules and to irregular absorption from scar tissue. The dose, on the other hand, does not depend on technique at all: the dose dial on the Body Pharm pen fixes it directly in milligrams.

Storage, handling and shelf life

Store the pen at 2–8 °C, protected from light, and never freeze it under any circumstances. Unopened, the shelf life is 24 months. Once the cartridge has been pierced for the first time, the pen is used up within 12 months. If there is no refrigerator available, the pen remains stable at room temperature for a maximum of 30 days, without going above 30 °C. Bring the pen to room temperature before injecting [1].

Handling before injection

Take the pen out of the refrigerator far enough in advance to allow the solution to reach room temperature. A cold injectable stings on the way in, and it distributes unevenly from the depot. Never freeze the pen: the freeze-thaw cycle precipitates the copper-peptide complex and generates visible particles.

Criteria for discarding

The solution in the cartridge should be clear, with a very pale blue tint owing to the Cu²⁺ chelate. The pen should be discarded if a deeper blue-green colour, cloudiness, visible particles or an odour coming through the septum is noticed. For anyone running parallel tissue-repair protocols, the storage rules apply equally to the BPC-157 and TB-500 dosing protocol, and the whole collection of peptide guides and dosing protocols covers handling compound by compound.

Combinations with GHK-Cu: the most common ones in research

In tissue-repair research, GHK-Cu is combined above all with BPC-157 and with TB-500, but as of 2026 not a single peer-reviewed human study has been published on any combination protocol that involves GHK-Cu. Anyone working with combinations should treat the rationale as mechanistic, not as something that has been clinically validated.

Two combinations in particular come up time and again in the literature and in the practice protocols:

• GHK-Cu + BPC-157, studied in tissue-repair and anti-inflammatory contexts, on the hypothesis that the copper-dependent remodelling activity of GHK-Cu complements the angiogenic and cytoprotective signalling of BPC-157.
• GHK-Cu + TB-500 (TB4 fragment), investigated in wound-healing and angiogenesis models, where TB-500 contributes actin sequestration and its effects on cell migration alongside the matrix and antioxidant pathways of GHK-Cu.

Combinations multiply the number of variables. If two peptides are given together from day one, attributing an observed change (skin tone, the speed of wound closure, shifts in inflammatory markers) to one specific compound becomes a matter of guesswork. The methodology described in the practice protocols is to run GHK-Cu as monotherapy for a full cycle of 4–6 weeks, record the end points, wash out for 2–4 weeks and only then introduce the second peptide. The detailed dosing rationale for the companion compounds is in the BPC-157 and TB-500 dosing protocol, and the wider index of peptide guides and dosing protocols covers the cycle structure of each compound in turn.

Frequently Asked Questions

As of 2026, GHK-Cu has no consensus chronotype and no human comparison between the routes of administration. The table below answers the questions that come up most often in enquiries from researchers.

A note on the comparison with the topical route

The most-cited reference on the cosmetic route of administration, Gorouhi and Maibach (2009) [8], falls well outside the 2023–2026 evidence window, and it predates the current subcutaneous practice protocols. Treat any comparison of potency between the routes as mechanistic reasoning, not as a measured bioequivalence.

How to continue

When a research plan involves combinations of regenerative peptides, the BPC-157 and TB-500 dosing protocol covers the handling and the cycle structure of the two compounds that are most often combined with GHK-Cu. The full index of peptide guides and dosing protocols brings together every one of the protocols on the site.

Ordering GHK-Cu from Body Pharm

Researchers are able to obtain pharmaceutical-grade GHK-Cu from Body Pharm, supplied as a pre-filled 50 mg multi-dose pen. Each and every batch is tested by a third party to confirm both its purity and its identity. The dose dial marks the dose in milligrams, so the daily 1 mg and 2 mg protocols are set directly on the pen.

On the site, GHK-Cu belongs to two neighbouring product groups: the skin peptides category, for research into dermal collagen and pigmentation, and the longevity peptides category, for work on gene expression and tissue remodelling.

All of the material is supplied exclusively for research purposes, and none of it is intended for use in humans [6].

Next steps

The planning of a research project usually starts by matching the research goal (skin remodelling, wound healing, anti-inflammatory action or hair follicle stimulation) to the dose table in the section "Dose ranges by research goal". Once the target dose and the cycle length have been fixed, GHK-Cu can be ordered from Body Pharm and that dose dialled on the pen as described in the section "Setting the dose on the GHK-Cu pen". If a combination with BPC-157 or with TB-500 is being planned, it is worth consulting the BPC-157 and TB-500 dosing protocol before starting the first cycle.

See GHK-Cu, Body Pharm → bodypharm.es/peptidos/ghk-cu

Sources

1. Body Pharm dosing protocol for the GHK-Cu pen (supplier specification, reviewed in October 2026). Supplier research protocol, not a peer-reviewed study.
2. Pickart L. The human tri-peptide GHK and tissue remodeling. J Biomater Sci Polym Ed. 2008. pubmed.ncbi.nlm.nih.gov/18644225
3. Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. Int J Mol Sci. 2018. pubmed.ncbi.nlm.nih.gov/29986520
4. Pickart L, et al. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. Biomed Res Int. 2015. pubmed.ncbi.nlm.nih.gov/26236730
5. Clinic and supplier practice literature on subcutaneous GHK-Cu (2023–2025), with no published controlled trial. Cited as a practice convention, not as evidence.
6. Directive 2001/83/EC, Article 1: definition of a medicinal product by presentation and by function; consolidated text on EUR-Lex. eur-lex.europa.eu — the legal basis for the fact that a reagent labelled "for research use only" remains subject to pharmaceutical regulation if it is presented for human use.
7. Turnlund JR, et al. Copper absorption, excretion, and retention by young men consuming low dietary copper determined by using the stable isotope 65Cu. Am J Clin Nutr. 1998. pubmed.ncbi.nlm.nih.gov/9625096
8. Gorouhi F, Maibach HI. Role of topical peptides in preventing or treating aged skin. Int J Cosmet Sci. 2009. pubmed.ncbi.nlm.nih.gov/19570099